(CORT) Corcept Therapeutics - Ratings and Ratios
Hormonemodulator, Korlym, Relacorilant, Dazucorilant, Miricorilant
CORT EPS (Earnings per Share)
CORT Revenue
Description: CORT Corcept Therapeutics
Corcept Therapeutics Incorporated is a pharmaceutical company focused on developing medications for severe endocrine, oncologic, metabolic, and neurologic disorders. The companys lead product, Korlym, is used to treat hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushings syndrome. Korlym has shown significant revenue growth, contributing substantially to the companys financials.
The companys pipeline includes several promising candidates: relacorilant, which is in Phase III trials for hypercortisolism and platinum-resistant ovarian tumors; dazucorilant, in Phase II trials for amyotrophic lateral sclerosis; and miricorilant, also in Phase IIb trials for metabolic dysfunction-associated steatohepatitis. These candidates target various high-value therapeutic areas, indicating potential for future growth.
From a financial perspective, Corcept Therapeutics has a market capitalization of approximately $7.6 billion, with a forward P/E ratio of 55.25, indicating a relatively high valuation likely due to its growth prospects. The Return on Equity (RoE) stands at 20.46%, suggesting effective use of shareholder capital. Key Performance Indicators (KPIs) to watch include revenue growth from Korlym sales, progression of pipeline candidates through clinical trials, and the companys ability to expand its therapeutic areas.
Analyzing the companys progress requires monitoring its cash position, R&D expenses, and milestones achieved in clinical trials. With a strong pipeline and a marketed product, Corcept Therapeutics is positioned for potential long-term growth, contingent on successful trial outcomes and effective commercialization strategies.
CORT Stock Overview
| Market Cap in USD | 9,289m |
| Sub-Industry | Pharmaceuticals |
| IPO / Inception | 2004-04-14 |
CORT Stock Ratings
| Growth Rating | 85.8% |
| Fundamental | 83.2% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | 37.5% |
| Analyst Rating | 4.50 of 5 |
CORT Dividends
Currently no dividends paidCORT Growth Ratios
| Growth Correlation 3m | 67.9% |
| Growth Correlation 12m | 79.6% |
| Growth Correlation 5y | 74.7% |
| CAGR 5y | 37.38% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.82 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.85 |
| Sharpe Ratio 12m | 0.04 |
| Alpha | 45.93 |
| Beta | 0.461 |
| Volatility | 44.13% |
| Current Volume | 1171.3k |
| Average Volume 20d | 843.2k |
| Stop Loss | 68.3 (-4.5%) |
| Signal | -0.59 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (132.5m TTM) > 0 and > 6% of Revenue (6% = 43.0m TTM) |
| FCFTA 0.22 (>2.0%) and ΔFCFTA 5.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 41.68% (prev 80.77%; Δ -39.10pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 182.2m > Net Income 132.5m (YES >=105%, WARN >=100%) |
| Net Debt (-96.1m) to EBITDA (103.8m) ratio: -0.93 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.06 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (120.5m) change vs 12m ago 8.31% (target <= -2.0% for YES) |
| Gross Margin 98.37% (prev 98.49%; Δ -0.12pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 94.45% (prev 79.72%; Δ 14.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.20 (EBITDA TTM 103.8m / Interest Expense TTM -24.3m) >= 6 (WARN >= 3) |
Altman Z'' 9.59
| (A) 0.37 = (Total Current Assets 443.1m - Total Current Liabilities 144.7m) / Total Assets 801.7m |
| (B) 0.75 = Retained Earnings (Balance) 599.4m / Total Assets 801.7m |
| (C) 0.13 = EBIT TTM 102.0m / Avg Total Assets 758.1m |
| (D) 3.63 = Book Value of Equity 601.9m / Total Liabilities 165.9m |
| Total Rating: 9.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 83.19
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 2.01% = 1.01 |
| 3. FCF Margin 25.18% = 6.29 |
| 4. Debt/Equity 0.01 = 2.50 |
| 5. Debt/Ebitda -0.93 = 2.50 |
| 6. ROIC - WACC (= 9.44)% = 11.80 |
| 7. RoE 20.10% = 1.67 |
| 8. Rev. Trend 95.66% = 7.17 |
| 9. EPS Trend -5.24% = -0.26 |
What is the price of CORT shares?
Over the past week, the price has changed by -20.39%, over one month by +2.88%, over three months by -1.70% and over the past year by +57.90%.
Is Corcept Therapeutics a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CORT is around 84.94 USD . This means that CORT is currently undervalued and has a potential upside of +18.75% (Margin of Safety).
Is CORT a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CORT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 135.3 | 89.1% |
| Analysts Target Price | 135.3 | 89.1% |
| ValueRay Target Price | 94 | 31.5% |
Last update: 2025-10-04 05:01
CORT Fundamental Data Overview
P/E Trailing = 78.7054
P/E Forward = 26.3158
P/S = 12.9713
P/B = 14.1668
P/EG = 0.61
Beta = 0.461
Revenue TTM = 716.1m USD
EBIT TTM = 102.0m USD
EBITDA TTM = 103.8m USD
Long Term Debt = 6.61m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.02m USD (from shortTermDebt, last quarter)
Debt = 6.61m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -96.1m USD (from netDebt column, last quarter)
Enterprise Value = 8.95b USD (9.29b + Debt 6.61m - CCE 342.2m)
Interest Coverage Ratio = -4.20 (Ebit TTM 102.0m / Interest Expense TTM -24.3m)
FCF Yield = 2.01% (FCF TTM 180.3m / Enterprise Value 8.95b)
FCF Margin = 25.18% (FCF TTM 180.3m / Revenue TTM 716.1m)
Net Margin = 18.51% (Net Income TTM 132.5m / Revenue TTM 716.1m)
Gross Margin = 98.37% ((Revenue TTM 716.1m - Cost of Revenue TTM 11.7m) / Revenue TTM)
Gross Margin QoQ = 98.23% (prev 98.47%)
Tobins Q-Ratio = 11.17 (Enterprise Value 8.95b / Total Assets 801.7m)
Interest Expense / Debt = 54.22% (Interest Expense 3.58m / Debt 6.61m)
Taxrate = -10.91% (negative due to tax credits) (-3.46m / 31.7m)
NOPAT = 113.1m (EBIT 102.0m * (1 - -10.91%)) [negative tax rate / tax credits]
Current Ratio = 3.06 (Total Current Assets 443.1m / Total Current Liabilities 144.7m)
Debt / Equity = 0.01 (Debt 6.61m / totalStockholderEquity, last quarter 635.8m)
Debt / EBITDA = -0.93 (Net Debt -96.1m / EBITDA 103.8m)
Debt / FCF = -0.53 (Net Debt -96.1m / FCF TTM 180.3m)
Total Stockholder Equity = 659.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 16.53% (Net Income 132.5m / Total Assets 801.7m)
RoE = 20.10% (Net Income TTM 132.5m / Total Stockholder Equity 659.4m)
RoCE = 15.31% (EBIT 102.0m / Capital Employed (Equity 659.4m + L.T.Debt 6.61m))
RoIC = 17.15% (NOPAT 113.1m / Invested Capital 659.4m)
WACC = 7.70% (E(9.29b)/V(9.30b) * Re(7.71%) + (debt cost/tax rate unavailable))
Discount Rate = 7.71% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 4.24%
[DCF Debug] Terminal Value 78.25% ; FCFE base≈157.5m ; Y1≈157.1m ; Y5≈165.8m
Fair Price DCF = 27.85 (DCF Value 2.93b / Shares Outstanding 105.4m; 5y FCF grow -0.90% → 3.0% )
EPS Correlation: -5.24 | EPS CAGR: -49.34% | SUE: -1.85 | # QB: 0
Revenue Correlation: 95.66 | Revenue CAGR: 26.56% | SUE: -0.40 | # QB: 0
Additional Sources for CORT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle